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Clonal dissemination of extended-spectrum -lactamases (ESBL) in 170 Escherichia coli isolates and 70
Klebsiella pneumoniae isolates from a nationwide study of 40 Spanish centers in 2000 was not observed in most
centers. The most prevalent ESBL were CTX-M-9 (27.3%), SHV-12 (23.9%), and CTX-M-14 (20.5%) for E. coli
and TEM-3 (16.7%) and TEM-4 (25%) for K. pneumoniae. A new ESBL, TEM-133, with mutations L21F, E104K,
and R164S, was identified.
The production of -lactamases is the most relevant resis-
tance mechanism against -lactam antimicrobials in gram-neg-
ative organisms. Extended-spectrum -lactamases (ESBL) of
the TEM-, SHV-, OXA-, and, more recently, CTX-M-type
enzymes have been described in many countries, including
Spain (5, 6, 16).
The first ESBL-producing strain described in Spain was iso-
lated in 1988, with several local ESBL outbreaks reported in
Madrid (1, 5, 6) and Barcelona (14) since then. A nationwide
epidemiological study was conducted in our country in 2000,
revealing that the prevalences of ESBL-producing Klebsiella
pneumoniae and Escherichia coli strains were 2.7% and 0.5%,
respectively (8). Now we describe the clonal relationship and
the susceptibility to antimicrobial agents of ESBL-producing
E. coli and K. pneumoniae strains isolated in this study and also
describe the molecular characterization of ESBL produced by
these strains.
Bacterial isolates. Two hundred and forty clinical isolates
(170 E. coli isolates and 70 K. pneumoniae isolates) corre-
sponding to the GEIH-BLEE 2000 Project were included in
the study (8). In this project, the prevalences of ESBL-produc-
ing E. coli and K. pneumoniae strains were evaluated over a
period of 4 months. A significant number of E. coli isolates
(51%) were derived from nonhospitalized patients. The organ-
isms were identified to the species level by using the API 20E
system (bioMérieux, Marcy-l’Étoile, France). ESBL produc-
tion was confirmed by broth microdilution according to
NCCLS guidelines (12).
Antimicrobial susceptibility testing. Broth microdilution as-
says were conducted with Mueller-Hinton broth according to
NCCLS guidelines (12). The following antimicrobial agents
were obtained from Sigma-Aldrich (Madrid, Spain): amoxicil-
lin, cefotaxime, ceftazidime, cefoxitin, piperacillin, amikacin,
gentamicin, tobramycin, ciprofloxacin, and co-trimoxazole.
The following antimicrobial agents were obtained from their
respective manufacturers: cefepime and cefpodoxime (Aventis
Pharma, Madrid, Spain), aztreonam (Bristol-Myers-Squibb,
Madrid, Spain), cefotetan and meropenem (AstraZeneca, Ma-
drid, Spain), imipenem (Merck, Sharp & Dohme, Madrid,
Spain), tazobactam (Wyeth-Lederle, Madrid, Spain), clavu-
lanic acid (GSK, Madrid, Spain), and ticarcillin (GSK). E. coli
ATCC 25922 and ATCC 35218, K. pneumoniae ATCC 700603,
Pseudomonas aeruginosa ATCC 27853, and Staphylococcus au-
reus ATCC 29213 were used as control strains.
Conjugation experiments. Conjugation experiments were
carried out by a broth mating method. E. coli BM21 and E. coli
J53-AzR were used as recipients for mating experiments with
ESBL-producing strains susceptible to rifampin and azide, re-
spectively. Plates containing ceftazidime (1 g/ml) or cefo-
taxime (2 g/ml) and rifampin (100 g/ml), when using the E.
coli BM21 recipient, or azide (200 g/ml), when using the E.
coli J53-AzR recipient, were used to select transconjugants (5).
-Lactamase characterization. -Lactamases were charac-
terized by isoelectric focusing (IEF) as previously described
(3). Clonality was assessed by repetitive extragenic palindromic
(REP)-PCR (3, 15). Isolates showing more than two different
bands after electrophoresis of the PCR product and ethidium
bromide staining were considered not clonally related. ESBL-
encoding genes were characterized by PCR as described pre-
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Rosa (Granada), J. Gutiérrez (Granada), M. Gomáriz (San Sebastián,
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viously, using specific primers for TEM, SHV, CTX-M-1, and
CTX-M-9 groups (6, 15). PCR products were purified with the
Sephaglas BandPrep (Amersham Pharmacia Biotech, Uppsala,
Sweden) purification kit for direct sequencing. ESBL gene
sequences were developed with an ABI PRISM 377 sequencer
(Applied Biosystems, Perkin-Elmer, Foster City, CA).
Nucleotide sequence accession number. The sequence of the
novel -lactamase, TEM-133, has been deposited in GenBank
and assigned the accession number AY528425.
ESBL production was confirmed in 240 isolates (170 E. coli
isolates and 70 K. pneumoniae isolates). As shown in Table 1,
all isolates were susceptible to imipenem and meropenem. The
most active -lactam/-lactamase inhibitor combination was
piperacillin-tazobactam (85% and 74% susceptible E. coli and
K. pneumoniae isolates, respectively).
One hundred thirty-seven and 26 different REP-PCR pat-
terns were obtained for E. coli and K. pneumoniae, respec-
tively. In 37 of 40 hospitals, ESBL-producing E. coli isolates
were clonally unrelated. In three centers, more than one E. coli
isolate (n, 2 to 14) presented the same REP-PCR pattern. For
K. pneumoniae, the number of REP-PCR patterns per hospital
ranged from one to four. Four hospitals had only one K. pneu-
moniae REP-PCR pattern with more than eight isolates each.
The other patterns included only one or two isolates. Due to
the diversity of REP-PCR patterns, all E. coli isolates were
analyzed further. Based on REP-PCR and susceptibility pat-
terns, 49 K. pneumoniae isolates were subsequently studied.
ESBL-encoding genes were transferable in 73.7% and
73.0% of E. coli and K. pneumoniae isolates, respectively.
TEM-type -lactamases (IEF bands ranging from pI 5.4 to 6.5)
were detected in 132 E. coli isolates and 38 K. pneumoniae
isolates; SHV-type enzymes were detected (IEF bands from pI
7.0 to 8.2) in 64 E. coli isolates and 51 K. pneumoniae isolates;
and 85 E. coli isolates and 5 K. pneumoniae isolates had IEF
bands with pIs of 8 to 8.1 (Table 2). These last isolates had a
cefotaxime MIC greater than that of ceftazidime (consistent
with a CTX-M-type -lactamase). When two or more IEF
bands were present, those with a pI of 5.4 were assumed to be
TEM-1, and those with a pI of 7.6 in K. pneumoniae were
assumed to be SHV-1.
SHV-encoding genes were identified in 94% of K. pneu-
moniae isolates. ESBL-encoding genes were sequenced from
91 E. coli isolates and 26 K. pneumoniae isolates, based on pI
values and antimicrobial susceptibility profiles. In selected E.
coli isolates, TEM-type ESBL were identified as TEM-3,
TEM-4, TEM-10, TEM-20, TEM-24, TEM-26, TEM-28,
TEM-29, TEM-52, and TEM-116, and in K. pneumoniae
strains, TEM-type ESBL were identified as TEM-3, TEM-4,
and TEM-25. Three E. coli isolates and one K. pneumoniae
isolate had only one pI 5.4 IEF band, subsequently identified as
TEM-1. Twelve clonally related K. pneumoniae isolates recov-
ered from the same hospital and with a pI 5.6 IEF band had the
following mutations in their ESBL-encoding gene sequence
based on TEM-1: L21F, E104K, and R164S. This new enzyme,
found only in Tenerife (the Canary Islands), has been desig-
nated TEM-133 (Table 3). Sequencing of SHV-type ESBL-
encoding genes in selected E. coli isolates yielded SHV-2 and
SHV-12, and it yielded SHV-2, SHV-2a, SHV-5, and SHV-12
in K. pneumoniae isolates (Table 3). One K. pneumoniae isolate
had a single pI 7.6 IEF band, subsequently identified as SHV-1.
CTX-M-type ESBL-encoding genes sequenced in E. coli
strains corresponded to CTX-M-9, CTX-M-10, and CTX-M-
14. In K. pneumoniae isolates, CTX-M-10 was the only CTX-
M-type ESBL produced (Table 3). The most prevalent ESBL
TABLE 1. In vitro activity of several antimicrobial agents against ESBL-producing E. coli and K. pneumoniae isolates
Agent
E. coli K. pneumoniae
MIC range (g/ml) MIC50 (g/ml) MIC90 (g/ml) %S
a MIC range (g/ml) MIC50 (g/ml) MIC90 (g/ml) %S
Cefotaxime 0.06–64 64 64 0 0.03–64 32 64 0
Ceftazidime 0.5–64 16 64 0 2–64 32 64 0
Cefepime 0.03–64 8 64 0 0.03–64 2 64 0
Aztreonam 0.125–64 8 64 0 0.125–64 8 64 0
Cefpodoxime 0.5–512 128 256 0 0.25–512 64 256 0
Cefoxitin 1–256 4 16 76.5 1–256 4 8 94
Cefotetan 0.25–32 1 2 98 0.25–32 0.25 0.5 98.5
Amoxicillin-clavulanate (2:1) 2/1–128/64 8/4 32/16 69 4/2–128/64 16/8 32/16 40
Ticarcillin-clavulanate (2 g/ml) 0.5–1,024 128 1,024 13 0.5–1,024 256 1,024 7
Piperacillin-tazobactam (4 g/ml) 0.5–1,024 2 128 85 0.5–1,024 4 1,024 74
Imipenem 0.06–1 0.125 0.25 100 0.06–0.5 0.125 0.25 100
Meropenem 0.06–0.25 0.06 0.06 100 0.06–0.125 0.06 0.06 100
Amikacin 0.5–128 2 16 93.5 0.5–64 1 16 91
Gentamicin 0.125–128 1 128 66 0.5–128 32 128 33
Tobramycin 0.25–128 1 64 65 0.25–128 8 32 38.5
Ciprofloxacin 0.06–128 4 128 37.5 0.06–64 0.125 2 88.5
Co-trimoxazole 4.75/0.25–608/32 304/16 608/32 25 4.75/0.25–608/32 19/1 608/32 40
a %S, percent susceptibility.
TABLE 2. IEF bands expressed by E. coli and
K. pneumoniae isolates
pI
No. of indicated isolates (total) with indicated band
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in selected E. coli isolates were CTX-M-9 (24 isolates; 27.3%),
SHV-12 (21 isolates; 23.9%), and CTX-M-14 (18 isolates;
20.5%). The geographical distribution of ESBL in Spain is
shown in Fig. 1. In the strains producing either a single TEM-1
or SHV-1 enzyme, the phenotype consistent with ESBL pro-
duction could be caused by either an ESBL of another family
with the same pI or other mechanisms as previously described
(11, 18).
In the first nationwide study of clinical isolates of ESBL-
producing E. coli and K. pneumoniae carried out in Spain, the
prevalences of ESBL-producing E. coli and K. pneumoniae
isolates in 40 Spanish hospitals were 0.5% and 2.7%, respec-
tively (8). Other studies developed in Italy and France de-
scribed similar results for E. coli isolates (1.2% and 0.2%,
respectively) but higher values for K. pneumoniae isolates
(20% and 9.4%, respectively) (7, 17).
The molecular study of the selected strains in this study
revealed a highly diverse population structure with a low clonal
relationship among ESBL-producing E. coli strains (170
strains/137 clones), even in those isolated within the same
institution. Of the 70 K. pneumoniae isolates, 26 different REP-
PCR patterns were obtained. In some hospitals, all the isolates
were clonally related, indicating that in Spain, as has been
described in other countries, ESBL-producing K. pneumoniae
isolates are frequently involved in outbreaks (1, 4, 9, 14).
The most active antimicrobial agents against ESBL-produc-
ing E. coli and K. pneumoniae isolates were carbapenems
(100% susceptible) and amikacin. Among the -lactam/-lac-
tamase inhibitor combinations, piperacillin-tazobactam was
the most active agent against these microorganisms. The con-
currence of ciprofloxacin resistance with ESBL production,
particularly in isolates of K. pneumoniae, was also observed in
this study. The actual causes of this association are not well
known but may be related not only to target mutations in DNA
gyrase or topoisomerase IV but also to other mechanisms,
TABLE 3. TEM-, SHV-, and CTX-M-type ESBL detected in
E. coli (n  88) and K. pneumoniae (n  24) isolates
ESBL
type
ESBL (no. of isolates) in indicated strain
E. coli K. pneumoniae
TEM TEM-3 (3) TEM-3 (4)
TEM-4 (2) TEM-4 (6)
TEM-10 (2) TEM-25 (2)







SHV SHV-2 (4) SHV-2 (2)
SHV-12 (21) SHV-2a (1)
SHV-5 (1)
SHV-12 (3)
CTX-M CTX-M-9 (24) CTX-M-10 (3)
CTX-M-10 (4)
CTX-M-14 (18)
FIG. 1. Distribution of ESBL described in this study. Eco, Escherichia coli; Kp, Klebsiella pneumoniae.
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including porin loss, active efflux, and target protection (2, 10,
13).
Among ESBL-producing E. coli isolates, there was a great
variety of TEM-type ESBL, with TEM-3 being the most prev-
alent. In addition to TEM-3 and TEM-25 being detected in
some K. pneumoniae isolates, this is the first report of TEM-10,
TEM-20, TEM-26, TEM-28, TEM-52, and TEM-116 in Spain.
SHV-12 was the most prevalent SHV-type ESBL expressed by
E. coli isolates (16 of 33 hospitals). CTX-M-type ESBL, an
emerging group of Ambler class A plasmidic -lactamases,
were the most prevalent E. coli ESBL isolated in Spain (52.3%
of total sequenced ESBL; 23 of 40 hospitals), with 91% be-
longing to the CTX-M-9 group (52% CTX-M-9 and 39%
CTX-M-14). CTX-M-9 and CTX-M-14 were encountered in
several regions of Spain, whereas CTX-M-10 was found mostly
in the central region of Spain.
In conclusion, the great diversity of ESBL and the preva-
lences of clinical isolates of E. coli and K. pneumoniae produc-
ing these enzymes indicate that this is an important problem in
Spain. Microbiology laboratories need to be alert to the correct
identification and control of infections caused by such micro-
organisms.
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